3 Firms Drive $5B SPAC Deal For UK Diagnostic Testing Co.
Private equity-backed LumiraDx, a U.K.-based diagnostics testing company, will hit the public markets at a $5 billion valuation by combining with a health care-focused special purpose acquisition company, in a deal...To view the full article, register now.
Already a subscriber? Click here to view full article